Medtronic PLC $MDT is Kiltearn Partners LLP’s 9th Largest Position

Kiltearn Partners LLP trimmed its holdings in shares of Medtronic PLC (NYSE:MDT) by 7.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 232,761 shares of the medical technology company’s stock after selling 18,800 shares during the quarter. Medtronic accounts for about 4.1% of Kiltearn Partners LLP’s investment portfolio, making the stock its 9th biggest position. Kiltearn Partners LLP’s holdings in Medtronic were worth $20,290,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MDT. 1248 Management LLC purchased a new position in shares of Medtronic during the 1st quarter valued at approximately $26,000. Twin Tree Management LP bought a new stake in shares of Medtronic in the first quarter worth $29,000. Activest Wealth Management raised its holdings in Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares in the last quarter. GFG Capital LLC bought a new position in Medtronic during the 2nd quarter valued at $36,000. Finally, True Wealth Design LLC boosted its stake in Medtronic by 49.8% during the 2nd quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 140 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT opened at $105.13 on Thursday. The firm has a fifty day moving average of $95.68 and a 200-day moving average of $91.39. The company has a market cap of $134.85 billion, a price-to-earnings ratio of 28.96, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. Daiwa Capital Markets boosted their price target on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a report on Friday, September 12th. Leerink Partners set a $120.00 price target on Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Finally, UBS Group boosted their target price on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $109.72.

Insider Activity

In other news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.